Was Gerald being deceptive when the company shifte
Post# of 30028
Posted On: 10/27/2014 12:13:14 PM
Re: Loco motion #9743
Was Gerald being deceptive when the company shifted their near-term strategic focus of MANF from Parkinson's to RP and other ocular disorders? He has been very open with investors regarding their strategic plans. Sometimes those plans change as new information comes to light and interactions with potential partners and customers continue.
If the share price was higher and trading in the range we expect based on how we value this company, I doubt anyone would be suggesting he was being deceptive. Funny how that one factor can change an investor's perspective on management. The suggestion posted here that the street lacks confidence in Gerald and is reflected in the current share price isn't based in fact. If someone could point to any analyst reviews stating credibility issues or inexperience is resulting in a depressed share price, I might give that theory some value. But at present it's just a theory to explain the current share price. I'm not convinced the share price has anything to do with our CEO or his perception in the marketplace. The most likely explanation is our company is a pre-revenue biotech on the OTC and our stock is dominated at present by short-term traders and MMs who seize every opportunity to turn a quick profit, resulting in wide swings in share price. I believe this will become less common as we move into revenue producing growth.
Will any investor feel Gerald has been deceptive once LymPro revenues are coming in, and the share price responds accordingly?
If the share price was higher and trading in the range we expect based on how we value this company, I doubt anyone would be suggesting he was being deceptive. Funny how that one factor can change an investor's perspective on management. The suggestion posted here that the street lacks confidence in Gerald and is reflected in the current share price isn't based in fact. If someone could point to any analyst reviews stating credibility issues or inexperience is resulting in a depressed share price, I might give that theory some value. But at present it's just a theory to explain the current share price. I'm not convinced the share price has anything to do with our CEO or his perception in the marketplace. The most likely explanation is our company is a pre-revenue biotech on the OTC and our stock is dominated at present by short-term traders and MMs who seize every opportunity to turn a quick profit, resulting in wide swings in share price. I believe this will become less common as we move into revenue producing growth.
Will any investor feel Gerald has been deceptive once LymPro revenues are coming in, and the share price responds accordingly?
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼